Affiliation:
1. Hospital de São João, Portugal
2. Hospital de São João, Portugal; University Fernando Pessoa, Portugal
Abstract
Interferon beta (IFNβ) and glatiramer acetate (GA) were the first immunomodulators approved to the treatment of relapsing-remitting multiple sclerosis (MS) and clinically isolated syndromes. Despite the enlargement of the therapeutic armamentarium, IFNβ and GA remain the most widely drugs and the therapeutic mainstay of MS. OBJECTIVE: To review the mechanisms of action of IFNβ and GA and main clinical results in MS. RESULTS: IFNβ modulates T and B-cell activity and has effects on the blood-brain barrier. The well proved mechanism of GA is an immune deviation by inducing expression of anti-inflammatory cytokines. Some authors favor the neuroprotective role of both molecules. Clinical trials showed a 30% reduction on the annualized relapse rate and of T2 lesions on magnetic resonance. CONCLUSION: Although the precise mechanisms how IFNβ and GA achieve their therapeutics effects remain unclear, these drugs have recognized beneficial effects and possess good safety and tolerability profiles. The large clinical experience in treating MS patients with these drugs along almost two decades deserves to be emphasized, at a time where the appearance of drugs with more selective mechanisms of action, but potentially less safer, pave the way to a better selection of the most appropriate individualized treatment.
Subject
Neurology,Clinical Neurology
Reference59 articles.
1. Neurology in clinical practice;Lublin FD,2008
2. Multiple sclerosis: risk factors, prodromes, and potential causal pathways;Ramagopalan SV;Lancet Neurol,2010
3. Treatment of multiple sclerosis with human beta interferon;Goodin DS;Int MS J,2005
4. Interferon-beta: mechanism of action and dosing issues;Markowitz CE;Neurology,2007
5. Biologic effects of interferons: relevance to multiple sclerosis;Rudick RA;Mult Scler,1995
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献